This article originally appeared on HCPLive®. The FDA has granted breakthrough therapy designation (BTD) for pemvidutide for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). 1 ...
GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon ...
Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome ...
Altimmune Inc (NASDAQ:ALT) hosted a virtual R&D day on Thursday, marking the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments for pemvidutide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results